Projects per year
Search results
-
Active
靶向MIR31HG/LncHIFCAR 相關分子網絡在胰腺癌轉移和腫瘤微環境的研究－應用dasatinib老藥新用治療胰腺癌之研究: 探討MIR31HG與上皮間質轉化之角色(1/3)
8/1/23 → 7/31/24
Project: A - Government Institution › b - National Science and Technology Council
-
探討site-1蛋白酶抑制劑之抗肝癌分子機轉(2/3)
8/1/23 → 7/31/24
Project: A - Government Institution › b - National Science and Technology Council
-
Finished
Mechanistic Investigation of Anticancer Activity of the Site-1 Protease Inhibitor against Hepatocellular Carcinoma (1/3)
8/1/22 → 7/31/23
Project: A - Government Institution › b - National Science and Technology Council
-
應用dasatinib老藥新用治療胰腺癌之研究: 探討MIR31HG與上皮間質轉化之角色
1/1/22 → 12/31/22
Project: B - Project of TMU › h - Higher Education Sprout Project
-
探討長鏈非編碼核糖核酸MIR31HG調控胰臟癌EMT之作用
3/1/21 → 2/28/22
Project: C - Project of Alliance › o - Chi Mei Medical Center
-
抑制site-1蛋白酶引發肝癌細胞自我吞噬之研究
8/1/20 → 7/1/21
Project: A - Government Institution › b - National Science and Technology Council
-
透過老藥新用策略來開發以Stathmin 1為標靶之抗肝癌新藥
3/1/20 → 2/28/21
Project: C - Project of Alliance › n - Yuan's General Hospital
-
長鏈非編碼核糖核酸LncHIFCAR/MIR31HG調控的中心網絡在胰臟癌的轉譯研究-探討MIR31HG 調控胰臟癌EMT 及藥物治療反應之作用
1/1/19 → 12/1/19
Project: A - Government Institution › d - Ministry of Education
-
探討耐克螺對HMGA2高表現大腸直腸癌之抗癌作用
3/1/18 → 2/28/19
Project: C - Project of Alliance › n - Yuan's General Hospital
-
以肝細胞體外模式探討花草茶萃取物改善非酒精性脂肪肝炎之療效(花草茶萃取物之保健功效研究)
1/1/18 → 12/31/18
Project: C - Project of Alliance › l - National Taiwan Ocean University
-
不同APC基因狀態大腸直腸癌患者藥物治療之抗藥性機轉研究-探討miR-21調控大腸直腸癌細胞TET1/5-hydroxymethylcytosine表現對其化療反應之關聯(3/3)
8/1/16 → 7/31/17
Project: A - Government Institution › b - National Science and Technology Council
-
Role of miR-21 in Regulating TET I-Hydroxymethylcytosine and Chemotherapeutic Response in Colorectal Cancer (II)
8/1/15 → 7/31/16
Project: A - Government Institution › b - National Science and Technology Council
-
運用化學基因體學方法開發新穎核糖核?酸還原?抑制劑用以治療大腸直腸癌
5/1/15 → 4/30/16
Project: C - Project of Alliance › u - Taipei Medical University Shuang Ho Hospital
-
Role of miR-21 in Regulating TET I-Hydroxymethylcytosine and Chemotherapeutic Response in Colorectal Cancer (I)
8/1/14 → 7/31/15
Project: A - Government Institution › b - National Science and Technology Council
-
Investigation on the Epigenetic Regulation of Autophagy
8/1/14 → 7/31/15
Project: A - Government Institution › b - National Science and Technology Council
-
探討EZH2抑制劑UNC1999誘導大腸直腸癌細胞自噬之機轉
6/1/14 → 5/31/15
Project: C - Project of Alliance › u - Taipei Medical University Shuang Ho Hospital
-
大腸直腸癌已躍居世界上癌症死亡率第二名，屬於固體型腫瘤，缺氧常見於此類 腫瘤，並誘發HIF-1α 表現而導致抗藥性及預後較差，因此抑制HIF-1α 被視為新的抗 癌策略。Zebularine (Zeb)是較穩定之DNA methyltransferase (DNMT)抑制劑，可殺死癌 細胞而不影響正常細胞，對小鼠也不具毒性。我們初步結果顯示，Zeb 可抑制人類大 腸癌細胞株HCT116 之HIF-1α表現，代表Zeb 是治療大腸直腸癌之潛力藥物。我們的 初步也證明Zeb對HCT116具毒殺性，對小鼠大腸癌也有療效。細胞自我吞噬(autophagy) 是指細胞在惡劣環境下，經由吞噬細胞內物質產生能量渡過外界壓力的一種保護機 制；也有研究報導指出，藥物會誘導癌細胞產生autophagy，造成細胞過度吞噬其內容 物而死亡，因此，autophagy在癌細胞為保護或是引發毒殺作用，目前仍無定論。缺氧 也會透過HIF-1α 導致autophagy 而促進細胞存活，但嚴重缺氧或無氧狀態則可透過活 化AMPK及unfolded protein response (UPR)造成autophagic cell death。我們初步結果顯 示，除抑制HIF-1α 表現外，Zeb 也可活化AMPK、UPR/ER stress、以及autophagy， 因此我們推測Zeb 可在缺氧狀態下，促進autophagic cell death。3 年內我們將執行4 項 目標： (1) 探討Zeb 在各種癌細胞及活體模式之抗癌作用。（第一年） (2) 研究Zeb 抑制HIF-1α表現之分子機轉。（第一年到第二年） (3) 研究Zeb 誘發autophagy之分子機轉。（第二年到第三年） (4) 探討Zeb 對缺氧導致抗藥性之作用。（第三年）
8/1/13 → 7/31/14
Project: A - Government Institution › b - National Science and Technology Council
-
探討DNMT抑制劑治療大腸直腸癌之新機轉
5/1/13 → 4/30/14
Project: C - Project of Alliance › u - Taipei Medical University Shuang Ho Hospital
-
-
Targeting Hif-1α by Zebularine for the Treatment of Colorectal Cancers
8/1/12 → 7/31/13
Project: A - Government Institution › b - National Science and Technology Council